Brokerages Set SAB Biotherapeutics, Inc. (NASDAQ:SABS) PT at $12.00

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) have received an average rating of “Moderate Buy” from the eleven research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $12.00.

A number of research firms have recently commented on SABS. Wall Street Zen upgraded shares of SAB Biotherapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday. Citigroup assumed coverage on shares of SAB Biotherapeutics in a report on Friday, May 22nd. They issued a “buy” rating and a $11.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of SAB Biotherapeutics in a research note on Monday, June 15th. Weiss Ratings cut shares of SAB Biotherapeutics from a “sell (d+)” rating to a “sell (e+)” rating in a research note on Thursday, August 6th. Finally, Jefferies Financial Group initiated coverage on SAB Biotherapeutics in a research report on Wednesday, May 20th. They set a “buy” rating and a $11.00 target price for the company.

SAB Biotherapeutics Trading Down 1.3%

NASDAQ SABS opened at $3.75 on Tuesday. SAB Biotherapeutics has a 52 week low of $1.85 and a 52 week high of $5.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.22 and a current ratio of 9.22. The stock’s 50 day moving average price is $3.71 and its two-hundred day moving average price is $3.82. The stock has a market capitalization of $341.21 million, a price-to-earnings ratio of -2.88 and a beta of 0.53.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.28) earnings per share for the quarter, hitting the consensus estimate of ($0.28). As a group, analysts anticipate that SAB Biotherapeutics will post -1.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SAB Biotherapeutics

Large investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP bought a new position in SAB Biotherapeutics during the 3rd quarter worth $32,000. ADAR1 Capital Management LLC acquired a new position in SAB Biotherapeutics during the 3rd quarter worth about $30,000. Virtu Financial LLC bought a new stake in shares of SAB Biotherapeutics in the 3rd quarter valued at about $40,000. RA Capital Management L.P. bought a new stake in shares of SAB Biotherapeutics in the 3rd quarter valued at about $8,847,000. Finally, Vivo Capital LLC acquired a new stake in shares of SAB Biotherapeutics in the third quarter valued at about $22,954,000. 7.82% of the stock is currently owned by institutional investors.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.